Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6-methylguanine-DNA methyltransferase promoter methylation in patients with gliomas

被引:29
作者
Zhang, Simin [2 ,3 ]
Sun, Huaiqiang [2 ]
Su, Xiaorui [2 ,3 ]
Yang, Xibiao [1 ,3 ,4 ]
Wang, Weina [2 ]
Wan, Xinyue [2 ]
Tan, Qiaoyue [2 ,5 ,6 ]
Chen, Ni [7 ]
Yue, Qiang [1 ,3 ,4 ]
Gong, Qiyong [2 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Radiol, 37 GuoXue Xiang, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Funct & Mol Imaging Key Lab Sichuan Prov, Huaxi MR Res Ctr HMRRC,Dept Radiol, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Huaxi Glioma Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Div Radiat Phys, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[7] Sichuan Univ, Dept Pathol, West China Hosp, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
automated machine learning; glioma; isocitrate dehydrogenase mutation; O-6‐ methylguanine‐ DNA methyltransferase promoter methylation; tree‐ based optimization tool; GRADE GLIOMA; GLIOBLASTOMA; FEATURES; TEMOZOLOMIDE; SURVIVAL; IDH1;
D O I
10.1002/jmri.27498
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Combining isocitrate dehydrogenase mutation (IDHmut) with O-6-methylguanine-DNA methyltransferase promoter methylation (MGMTmet) has been identified as a critical prognostic molecular marker for gliomas. The aim of this study was to determine the ability of glioma radiomics features from magnetic resonance imaging (MRI) to predict the co-occurrence of IDHmut and MGMTmet by applying the tree-based pipeline optimization tool (TPOT), an automated machine learning (autoML) approach. This was a retrospective study, in which 162 patients with gliomas were evaluated, including 58 patients with co-occurrence of IDHmut and MGMTmet and 104 patients with other status comprising: IDH wildtype and MGMT unmethylated (n = 67), IDH wildtype and MGMTmet (n = 36), and IDHmut and MGMT unmethylated (n = 1). Three-dimensional (3D) T1-weighted images, gadolinium-enhanced 3D T1-weighted images (Gd-3DT1WI), T2-weighted images, and fluid-attenuated inversion recovery (FLAIR) images acquired at 3.0 T were used. Radiomics features were extracted from FLAIR and Gd-3DT1WI images. The TPOT was employed to generate the best machine learning pipeline, which contains both feature selector and classifier, based on input feature sets. A 4-fold cross-validation was used to evaluate the performance of automatically generated models. For each iteration, the training set included 121 subjects, while the test set included 41 subjects. Student's t-test or a chi-square test was applied on different clinical characteristics between two groups. Sensitivity, specificity, accuracy, kappa score, and AUC were used to evaluate the performance of TPOT-generated models. Finally, we compared the above metrics of TPOT-generated models to identify the best-performing model. Patients' ages and grades between two groups were significantly different (p = 0.002 and p = 0.000, respectively). The 4-fold cross-validation showed that gradient boosting classifier trained on shape and textual features from the Laplacian-of-Gaussian-filtered Gd-3DT1 achieved the best performance (average sensitivity = 81.1%, average specificity = 94%, average accuracy = 89.4%, average kappa score = 0.76, average AUC = 0.951). Using autoML based on radiomics features from MRI, a high discriminatory accuracy was achieved for predicting co-occurrence of IDHmut and MGMTmet in gliomas. Level of Evidence 3 Technical Efficacy Stage 3
引用
收藏
页码:197 / 205
页数:9
相关论文
共 50 条
[31]   O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation [J].
Kreth, Simone ;
Thon, Niklas ;
Eigenbrod, Sabina ;
Lutz, Juergen ;
Ledderose, Carola ;
Egensperger, Rupert ;
Tonn, Joerg C. ;
Kretzschmar, Hans A. ;
Hinske, Ludwig C. ;
Kreth, Friedrich W. .
PLOS ONE, 2011, 6 (02)
[32]   Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? [J].
Gramatzki, Dorothee ;
Felsberg, Joerg ;
Hentschel, Bettina ;
Wolter, Marietta ;
Schackert, Gabriele ;
Westphal, Manfred ;
Regli, Luca ;
Thon, Niklas ;
Tatagiba, Marcos ;
Wick, Wolfgang ;
Schlegel, Uwe ;
Krex, Dietmar ;
Matschke, Jakob ;
Roth, Patrick ;
Suresh, Marian P. ;
Kamp, Marcel A. ;
Rushing, Elisabeth J. ;
Pietsch, Torsten ;
von Deimling, Andreas ;
Sabel, Michael ;
Loeffler, Markus ;
Weller, Michael ;
Reifenberger, Guido .
EUROPEAN JOURNAL OF CANCER, 2021, 147 :84-94
[33]   Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas [J].
Adrian F. Ochsenbein ;
Adrian D. Schubert ;
Erik Vassella ;
Luigi Mariani .
Journal of Neuro-Oncology, 2011, 103 :343-351
[34]   Frequency of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Cytological Samples From Small Cell Lung Cancer [J].
Miglio, Umberto ;
Mezzapelle, Rosanna ;
Paganotti, Alessia ;
Veggiani, Claudia ;
Mercalli, Francesca ;
Mancuso, Giuseppe ;
Gaudino, Erica ;
Rena, Ottavio ;
Buosi, Roberta ;
Boldorini, Renzo .
DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) :947-952
[35]   O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation Detection in Glioma Tumors by a Novel Fluorescence Polarization Assay [J].
Wu, Zhongliang ;
Zhang, Ju ;
Cheng, Hong ;
Liang, Ping ;
Guo, Yanhai ;
Yan, Zhen ;
Zhao, Jinrong .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2010, 19 (04) :232-235
[36]   Defining the recommended gray zone in O6-methylguanine-DNA methyltransferase promoter methylation pyrosequencing reporting: A robust, translatable method to implement new EANO guidelines [J].
Taylor, Polly ;
Cruickshank, Gabrielle ;
Wildman, Jack ;
Doyle, George ;
Whittaker, Ed ;
Walker, Sara ;
Mckeeve, Claire ;
Faulkner, Claire ;
Yarram-Smith, Laura ;
White, Paul ;
Kurian, Kathreena M. .
NEURO-ONCOLOGY ADVANCES, 2025, 7 (01)
[37]   miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase [J].
Huiyuan Chen ;
Xinyi Li ;
Wenbin Li ;
Huyong Zheng .
Journal of Translational Medicine, 13
[38]   miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase [J].
Chen, Huiyuan ;
Li, Xinyi ;
Li, Wenbin ;
Zheng, Huyong .
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13 :1
[39]   O6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment [J].
Adachi, Jun-ichi ;
Mishima, Kazuhiko ;
Wakiya, Kenji ;
Suzuki, Tomonari ;
Fukuoka, Kohei ;
Yanagisawa, Takaaki ;
Matsutani, Masao ;
Sasaki, Atsushi ;
Nishikawa, Ryo .
JOURNAL OF NEURO-ONCOLOGY, 2012, 107 (01) :147-153
[40]   O6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment [J].
Jun-ichi Adachi ;
Kazuhiko Mishima ;
Kenji Wakiya ;
Tomonari Suzuki ;
Kohei Fukuoka ;
Takaaki Yanagisawa ;
Masao Matsutani ;
Atsushi Sasaki ;
Ryo Nishikawa .
Journal of Neuro-Oncology, 2012, 107 :147-153